UK government inks deal for 60 million doses of Valneva COVID-19 vaccine
Valneva has agreed to supply the UK government with 60 million doses of its potential COVID-19 vaccine by the second half of 2021.
List view / Grid view
Valneva has agreed to supply the UK government with 60 million doses of its potential COVID-19 vaccine by the second half of 2021.
The ABPI has said that the new UK-Japan free trade agreement will benefit the pharma industry, providing continuity for life science businesses.
The ABPI has responded to new guidance, intended to prepare pharma companies for the end of the Brexit transition period, from the MHRA.
Grant Courtney explains why traceability is vital for the current pandemic as it would guarantee that COVID-19 vaccines are safe, effective and suitably distributed.
The International Air Cargo Association and Pharma.Aero will form a joint working group to provide air cargo guidance to the logistics industry for the transportation of COVID-19 vaccines.
Mike Owen details how supply chains have been disrupted by COVID-19 and why smart information management can offer a new source of renewed trust.
The UK government has written an open letter to medicine suppliers, outlining how supply can be maintained after the end of the Brexit transition period.
According to a new report from the International Trade Committee, the UK's medicine supply chain was able to withstand the challenge of COVID-19, but must be optimised for a potential second wave of the virus.
The alliance between Chronicled and Deloitte intends to enhance security and efficiency in the pharma supply chain by bring to market new blockchain-powered solutions.
Coronavirus or COVID-19 is currently the leading cause of mortality worldwide. With a patient database of 4,150,343 active cases (as of 28 June 2020), it is the most hit word on the internet today. Besides this catastrophe, the world has been facing a severe shortage of healthcare facilities, which has…
Over a year since the EU FMD came into force, false alerts remain a problem preventing the realisation of the full benefits of the directive. Grant Courtney examines the reasons behind these alerts occurring and looks at the action stakeholders must now take.
Dr Madhav Durbha explains the importance of implementing and ensuring stable supply chains to deliver potential COVID-19 vaccines.
Many pharmaceutical companies have complicated supply chains that are inefficient and ill-equipped to deal with current demands. This article explores how digitalising the healthcare supply chain can address the pharmaceutical sector's increasing financial-, capacity- and waste-related strains associated with our ageing population and the soaring costs of new treatments.
For over 30 years, pharmaceutical and medical device product release has relied solely on endotoxin assays using Limulus Amebocyte Lysate (LAL). This article addresses the potential risks associated with relying on a single raw material in a fragile supply chain and explores alternative testing options.
Included in this in-depth focus are articles on why digitalising the pharma supply chain could prevent inefficiencies and how packaging design can improve patient engagement and adherence.